Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 19, 2016

Shield Therapeutics launches Feraccru to treat IDA in IBD patients in UK

Specialist pharmaceutical company Shield Therapeutics has launched Feraccru (ferric maltol) within the UK to treat adults with iron deficiency anaemia (IDA) in patients affected with inflammatory bowel disease (IBD), who have previously failed on oral iron (ferrous) products.

By Lopamudra Roy

IDA

Specialist pharmaceutical company Shield Therapeutics has launched Feraccru (ferric maltol) within the UK to treat adults with iron deficiency anaemia (IDA) in patients affected with inflammatory bowel disease (IBD), who have previously failed on oral iron (ferrous) products.

The two primary forms of IBD include Crohn’s Disease and Ulcerative Colitis, while IDA is the most common non-intestinal symptom of IBD, affecting between 36% to 76% of patients.

Shield Therapeutics founder and chief executive officer Carl Sterritt said: "As part of our ongoing commitment to improve the lives of IDA patients with IBD, we are very pleased to report that they now have access to Feraccru in the UK.

"Based on the highly compelling results generated throughout its clinical trials, we believe that Feraccru is an exciting new oral treatment option for patients who have failed on oral ferrous products. These patients may previously have had to progress to IV iron or might have received no treatment at all.

"As part of our ongoing commitment to improve the lives of IDA patients with IBD, we are very pleased to report that they now have access to Feraccru in the UK."

"We would like to thank all the people who took part in our clinical trials, the investigators and everyone involved in bringing this important product to the market."

The symptoms of IDA, such as fatigue, in IBD patients can significantly affect their daily activities, including their ability to work.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Feraccru (ferric maltol), which is an effective oral ferric iron treatment for IDA, provides a new oral ferric alternative for adult IBD patients with IDA who have failed oral ferrous products.

Feraccru addresses an unmet need in IBD care and also serves as a well-tolerated oral alternative to intravenous (IV) iron in mild to moderate IBD patients.


Image: Micrograph showing inflammation of the large bowel in a case of inflammatory bowel disease. Photo: courtesy of Nephron.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU